Helge Lund served as chief executive of BG Group plc, UK, the global oil and gas company, from 2015 to 2016 when the company was acquired by Shell. Prior to that Mr Lund served as president and CEO of Statoil ASA, Norway, from 2004 to 2014. From 2002 to 2004 Mr Lund served as president & CEO of Aker Kvaerner ASA, Norway, an industrial conglomerate with operations in oil and gas, engineering and construction, pulp and paper and shipbuilding. Prior to this Mr Lund has also held executive positions in Aker RGI ASA, Norway, an industrial holding company, and Hafslund Nycomed, Norway, an industrial group with business activities in pharmaceuticals and energy. Mr Lund serves as operating advisor to Clayton Dubilier & Rice, US, and as senior advisor to McKinsey & Co., US. Mr Lund is a member of the boards of Schlumberger Ltd., Curaçao, and P/F Tjaldur, Faroe Islands. Furthermore, Mr Lund is a member of the Board of Trustees of the International Crisis Group. Mr Lund has an MA in Economics from the Norwegian School of Economics & Business Administration (NHH), Norway, from 1987 and an MBA from INSEAD, France, from 1991. From 2014 to 2015 Mr Lund was a member of the Board of Directors of Novo Nordisk A/S. Mr Lund was elected to the Board of Novo Nordisk A/S again in March 2017. His term as a board member expires in March 2018. In March 2017, the Board of Directors of Novo Nordisk A/S assessed that Mr Lund is regarded as an independent board member as defined in Section 3.2.1 of the Recommendations on Corporate Governance designated by Nasdaq Copenhagen. Mr Lund became a member of the Audit Committee at Novo Nordisk A/S in March 2017. In March 2017, the Board of Directors of Novo Nordisk A/S designated Mr Lund as financial expert as defined by the US Securities and Exchange Commission (SEC) and assessed that Mr Lund qualifies as independent pursuant to the US Securities Exchange Act. In addition, the Board of Directors of Novo Nordisk A/S assessed that Mr Lund has competences in accounting and auditing as required by the Danish Act on Approved Auditors and Audit Firms. Mr Lund became a member of the Nomination Committee at Novo Nordisk A/S in March 2017. In January 2017, the Board of Directors assessed that the special competences possessed by Mr Lund that are important for the performance of his duties are his extensive executive and board experience in large multinational companies headquartered in Scandinavia within regulated markets and significant financial knowledge. Mr Lund is a male Norwegian national, born October 1962. Helge Lund served as chief executive of BG Group plc, UK, the global oil and gas company, from 2015 to 2016 when the company was acquired by Shell. Prior to that Mr Lund served as president and CEO of Statoil ASA, Norway, from 2004 to 2014. From 2002 to 2004 Mr Lund served as president & CEO of Aker Kvaerner ASA, Norway, an industrial conglomerate with operations in oil and gas, engineering and construction, pulp and paper and shipbuilding. Prior to this Mr Lund has also held executive positions in Aker RGI ASA, Norway, an industrial holding company, and Hafslund Nycomed, Norway, an industrial group with business activities in pharmaceuticals and energy. Mr Lund serves as operating advisor to Clayton Dubilier & Rice, US, and as senior advisor to McKinsey & Co., US. Mr Lund is a member of the boards of Schlumberger Ltd., Curaçao, and P/F Tjaldur, Faroe Islands. Furthermore, Mr Lund is a member of the Board of Trustees of the International Crisis Group. Mr Lund has an MA in Economics from the Norwegian School of Economics & Business Administration (NHH), Norway, from 1987 and an MBA from INSEAD, France, from 1991. From 2014 to 2015 Mr Lund was a member of the Board of Directors of Novo Nordisk A/S. Mr Lund was elected to the Board of Novo Nordisk A/S again in March 2017. His term as a board member expires in March 2018. In March 2017, the Board of Directors of Novo Nordisk A/S assessed that Mr Lund is regarded as an independent board member as defined in Section 3.2.1 of the Recommendations on Corporate Governance designated by Nasdaq Copenhagen. Mr Lund became a member of the Audit Committee at Novo Nordisk A/S in March 2017. In March 2017, the Board of Directors of Novo Nordisk A/S designated Mr Lund as financial expert as defined by the US Securities and Exchange Commission (SEC) and assessed that Mr Lund qualifies as independent pursuant to the US Securities Exchange Act. In addition, the Board of Directors of Novo Nordisk A/S assessed that Mr Lund has competences in accounting and auditing as required by the Danish Act on Approved Auditors and Audit Firms. Mr Lund became a member of the Nomination Committee at Novo Nordisk A/S in March 2017. In January 2017, the Board of Directors assessed that the special competences possessed by Mr Lund that are important for the performance of his duties are his extensive executive and board experience in large multinational companies headquartered in Scandinavia within regulated markets and significant financial knowledge. Mr Lund is a male Norwegian national, born October 1962.

Pathology